Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Vertex Pharmaceuticals stock

Learn how to easily invest in Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals Inc is a biotechnology business based in the US. Vertex Pharmaceuticals shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Vertex Pharmaceuticals employs 3,900 staff and has a trailing 12-month revenue of around $8.4 billion.

How to buy shares in Vertex Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Vertex Pharmaceuticals stock price (NASDAQ: VRTX)

Use our graph to track the performance of VRTX stocks over time.

Vertex Pharmaceuticals shares at a glance

Information last updated 2022-10-02.
Latest market close$297.43
52-week range$176.36 - $305.95
50-day moving average $287.24
200-day moving average $261.76
Wall St. target price$310.54
PE ratio 23.7134
Dividend yield $0 (0%)
Earnings per share (TTM) $12.21

Buy Vertex Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vertex Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vertex Pharmaceuticals price performance over time

Historical closes compared with the close of $297.43 from 2022-10-03

1 week (2022-09-27) 4.46%
1 month (2022-09-02) 5.83%
3 months (2022-07-01) 3.52%
6 months (2022-04-01) 11.75%
1 year (2021-10-01) 64.92%
2 years (2020-10-02) 14.05%
3 years (2019-10-04) 72.50%
5 years (2017-10-04) 95.02%

Is Vertex Pharmaceuticals stock undervalued or overvalued?

Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vertex Pharmaceuticals's P/E ratio

Vertex Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Vertex Pharmaceuticals shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Vertex Pharmaceuticals's PEG ratio

Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3979. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Vertex Pharmaceuticals's EBITDA

Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 billion.

The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Vertex Pharmaceuticals financials

Revenue TTM $8.4 billion
Operating margin TTM 37.59%
Gross profit TTM $3.6 billion
Return on assets TTM 14.11%
Return on equity TTM 30.24%
Profit margin 38.26%
Book value $46.61
Market capitalisation $74.3 billion

TTM: trailing 12 months

Vertex Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Vertex Pharmaceuticals's total ESG risk score

Total ESG risk: 30.84

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 01/01/2019) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Vertex Pharmaceuticals's environmental score

Environmental score: 5.65/100

Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Vertex Pharmaceuticals's social score

Social score: 24.22/100

Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Vertex Pharmaceuticals's governance score

Governance score: 12.46/100

Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Vertex Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Vertex Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score 30.84
Total ESG percentile 44
Environmental score 5.65
Environmental score percentile 8
Social score 24.22
Social score percentile 8
Governance score 12.46
Governance score percentile 8
Level of controversy 2

Vertex Pharmaceuticals share dividends

We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.

Have Vertex Pharmaceuticals's shares ever split?

Vertex Pharmaceuticals's shares were split on a 2:1 basis on 24 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.

Vertex Pharmaceuticals share price volatility

Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $176.36 up to $305.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.4475. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).

Vertex Pharmaceuticals overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1. 8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc. ; Arbor Biotechnologies, Inc.

Frequently asked questions

What percentage of Vertex Pharmaceuticals is owned by insiders or institutions?
Currently 0.229% of Vertex Pharmaceuticals shares are held by insiders and 94.367% by institutions.
How many people work for Vertex Pharmaceuticals?
Latest data suggests 3,900 work at Vertex Pharmaceuticals.
When does the fiscal year end for Vertex Pharmaceuticals?
Vertex Pharmaceuticals's fiscal year ends in December.
Where is Vertex Pharmaceuticals based?
Vertex Pharmaceuticals's address is: 50 Northern Avenue, Boston, MA, United States, 02210
What is Vertex Pharmaceuticals's ISIN number?
Vertex Pharmaceuticals's international securities identification number is: US92532F1003
What is Vertex Pharmaceuticals's CUSIP number?
Vertex Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 92532F100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site